Recent studies have shown that ∼30% of both melanoma and lung carcinomas have at least one mutation in the IFNγ pathway, including JAK1, IFNGR1, or IFNGR2 (Cheon et al, 2014), and resistance to checkpoint inhibitors in patients is associated with JAK1/2 mutations (Shin et al, 2017). Here, IFNGR1 is linked to melanoma.